Miragen Therapeutics Inc (NASDAQ:MGEN) – Analysts at Jefferies Financial Group issued their Q1 2019 earnings per share (EPS) estimates for Miragen Therapeutics in a research note issued to investors on Wednesday, November 7th. Jefferies Financial Group analyst E. Yang expects that the medical research company will post earnings of ($0.37) per share for the quarter.

Several other analysts have also issued reports on the company. ValuEngine lowered Miragen Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 17th. Wedbush reissued an “outperform” rating and set a $19.00 price target on shares of Miragen Therapeutics in a report on Monday, October 8th. Cann reissued a “buy” rating and set a $19.00 price target on shares of Miragen Therapeutics in a report on Monday, October 1st. Finally, Zacks Investment Research lowered Miragen Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 11th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $15.34.

NASDAQ:MGEN opened at $3.91 on Friday. Miragen Therapeutics has a 52-week low of $3.85 and a 52-week high of $10.70. The company has a current ratio of 18.98, a quick ratio of 18.98 and a debt-to-equity ratio of 0.15.

Miragen Therapeutics (NASDAQ:MGEN) last issued its quarterly earnings data on Wednesday, November 7th. The medical research company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.03. Miragen Therapeutics had a negative return on equity of 48.25% and a negative net margin of 316.11%. The company had revenue of $0.94 million during the quarter, compared to analyst estimates of $1.89 million.

Several institutional investors have recently made changes to their positions in the company. BSW Wealth Partners lifted its position in shares of Miragen Therapeutics by 731.8% in the third quarter. BSW Wealth Partners now owns 184,959 shares of the medical research company’s stock valued at $9,294,000 after acquiring an additional 162,723 shares in the last quarter. BlackRock Inc. lifted its position in shares of Miragen Therapeutics by 1.4% in the third quarter. BlackRock Inc. now owns 1,411,753 shares of the medical research company’s stock valued at $7,878,000 after acquiring an additional 19,277 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Miragen Therapeutics in the third quarter valued at about $517,000. Northern Trust Corp lifted its position in shares of Miragen Therapeutics by 60.3% in the second quarter. Northern Trust Corp now owns 274,612 shares of the medical research company’s stock valued at $1,760,000 after acquiring an additional 103,348 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Miragen Therapeutics by 69.5% in the second quarter. Bank of New York Mellon Corp now owns 59,917 shares of the medical research company’s stock valued at $384,000 after acquiring an additional 24,575 shares in the last quarter. Institutional investors and hedge funds own 37.03% of the company’s stock.

In related news, Director Thomas E. Hughes purchased 10,000 shares of the business’s stock in a transaction on Thursday, October 11th. The stock was acquired at an average price of $4.77 per share, with a total value of $47,700.00. Following the completion of the acquisition, the director now owns 12,827 shares of the company’s stock, valued at approximately $61,184.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 18.90% of the company’s stock.

About Miragen Therapeutics

Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan.

Featured Article: Hedge Funds – How They Work For Investors

Earnings History and Estimates for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.